Candel Therapeutics (CADL) Fundamental Analysis: Revenue, Earnings & Valuation

4.55 / 10

Netural

Fundamental rating is neutral (4.5/10). Strengths include high cash‑to‑market (Cash‑MV) and excellent inventory turnover, while asset‑to‑market and income‑tax ratios lag. Overall, the balance sheet is healthy with ample cash runway, but valuation metrics suggest limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-0.08

Score1/3

Weight13.85%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight16.81%

1M Return6.65%

Gross profit margin (%)

Value48.34

Score1/3

Weight0.65%

1M Return0.36%

Profit-MV

Value0.68

Score3/3

Weight31.00%

1M Return9.40%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight0.39%

1M Return0.21%

Current assets turnover ratio

Value2.44

Score2/3

Weight3.63%

1M Return1.91%

Fixed assets turnover ratio

Value9771.06

Score3/3

Weight3.35%

1M Return1.76%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight8.35%

1M Return4.08%

Asset-MV

Value-0.55

Score0/3

Weight6.48%

1M Return2.73%

Cash-MV

Value0.03

Score2/3

Weight15.49%

1M Return6.19%

Is CADL fundamentally strong?

CADL scores 4.55/10 on fundamentals and holds a Fair valuation at present. Backed by its -64.58% ROE, 0.00% net margin, -9.23 P/E ratio, 6.79 P/B ratio, and 58.62% earnings growth, these metrics solidify its Netural investment rating.